Xiuning Le, Associate Professor, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared a post by Hussein Tawbi, a Professor at The University of Texas MD Anderson Cancer Center on X:
“Honored to present at Society for Immunotherapy of Cancer for HARMONi-A trial final OS. Echo Hussein Tawbi that we are marking evolution of PD-1 blockade.”
Quoting Hussein Tawbi’s post:
“Dr. Xiuning Le presenting Society for Immunotherapy of Cancer. FINAL OS results from ivonescimab + carbo/pem in TKI-refractory EGFR-NSCLC, HR 0.74, p=0.019. Benefit strongest in pts with brain mets HR 0.61, regimen approved in China. Impressive results marking evolution of PD-1 blockade.”
More posts featuring Xiuning Le on OncoDaily.